Huberman Lab

Peptides: The Science, Uses & Safety | Dr. Abud Bakri

Huberman Lab·June 2, 2026

OVERVIEW

This episode features Dr. Abud Bakri, an internal medicine physician, who provides a masterclass on peptides. The discussion spans FDA-approved peptides like GLP-1 agonists (Ozempic, Mounjaro, Retatrutide) and other widely discussed compounds such as BPC-157, GHK copper, Epitalon, Pinealon, and growth hormone secretagogues. Dr. Bakri delves into the science, uses, safety, and complex regulatory landscape surrounding these molecules, categorizing them by the presence or absence of known receptors.

KEY TOPICS

  • Peptide definition and categorization (known vs. unknown receptors)
  • BPC-157: Origin, animal studies, anecdotal human effects on tissue repair, gut health, and nerve regeneration, safety concerns (angiogenesis, tumor growth), legal status, and sourcing challenges
  • The peptide market: Compounding pharmacies, "gray market" suppliers, cost implications, and quality control issues
  • GLP-1 agonists (Ozempic, Mounjaro, Retatrutide): Efficacy for weight loss and diabetes, long-term implications, and effects on brain function and appetite
  • Pinealon (EDR): Origin (cortex extract), impact on REM sleep, cognitive performance, and genetic expression
  • Epitalon: Origin (pineal gland), effects on circadian rhythms, melatonin production, DNA repair, and anti-aging/longevity, primarily from Russian research
  • The thymus gland and thymic peptides (Thymosin Alpha, TB-500, Thymulin) for immune function, T-cell development, and anti-aging
  • GHK copper: Role in skin and hair health, collagen remodeling, and topical application, often used with red light therapy
  • Growth Hormone Secretagogues (Tesamorelin, Ipamorelin, MK-677): Benefits for somatopause, muscle growth, fat loss, and anti-aging, with associated risks like insulin insensitivity and prostate growth
  • The "Trinity Stack" or "Celebrity Protocol": Combining TRT, GLP-1s, and growth hormone modulation for rapid body transformation
  • General peptide safety, sourcing quality, the scarcity of human clinical data, and the importance of physician oversight
  • Challenges in peptide regulation, inconsistent nomenclature, and the future evolution of peptide medicine

MAIN TAKEAWAYS

  • Peptides represent a diverse and rapidly evolving area of medicine with significant potential to address a range of health issues, from tissue repair and immune function to metabolic health and longevity.
  • Many peptides, such as BPC-157, GHK copper, Epitalon, and Pinealon, demonstrate promising effects in animal studies and anecdotal human reports, but generally lack robust, independent human clinical trials, creating a challenging landscape for safe and effective use.
  • The regulatory environment for peptides is highly fragmented, leading to a "gray market" rife with quality control issues, mislabeling, and potential contamination, which poses substantial risks to consumers.
  • While FDA-approved GLP-1 agonists (e.g., Ozempic, Mounjaro, Retatrutide) are revolutionizing the treatment of obesity and diabetes, concerns persist regarding their long-term effects on brain function, metabolism, and the necessity of lifelong use.
  • Core biological processes like thymic and pineal gland function, crucial for immunity, circadian rhythms, and anti-aging, are influenced by specific peptides, highlighting under-explored avenues for health optimization.
  • It is crucial for individuals interested in peptides to seek guidance from knowledgeable physicians, ensure reliable sourcing from compounding pharmacies where legally permissible, and prioritize foundational health practices before considering peptide interventions.

NOTABLE QUOTES

"People are now stacking their GLP one as their insulin sensitivity tool, their growth hormone or their GHRH, and their andine modulation therapies as this trinity stack, trinity stack to get very fit, very healthy quickly."
"The reality is it's here. There is no pre GLP one world for us as clinicians, as health enthusiasts. We're in a post GLP one world, and everything kind of dictates downstream from that."
"What matters to where it touches, what receptor touches. Because our foger pond is more a similar to semi glutide. Both them are GLP one drugs on peptide one is not, then BBC is the semi gluetide. So like everyone online talk. About peptides are goodor peptides are bad, there's no. Actual scientific category of peptides that gives you a functional definition that's discussable between people."

Summarized with DriftNote — AI-powered podcast summaries

Try it free